A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

NCT02178397 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped lack of recruitment

Conditions

NSCLC Patients With EGFR Activating Mutation

Interventions

DRUG: ERLOTINIB WITH CHEMOTHERAPY
DRUG: CHEMOTHERAPY ONLY

Sponsor

Centre Francois Baclesse

Collaborators

[object Object]
[object Object]